Lung Cancer

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.

Two leading researchers discuss the role of the ALK signaling pathway and development into new ALK-targeted anticancer therapies.

There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.

Dr. Ross Camidge, from the University of Colorado Cancer Center, Discusses Resequencing Lung Cancer

The presence of specific molecular biomarkers may assist in determining the correct morphologic diagnosis of the particular cancer being examined.

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

Smokers are better able to remember the printed health-risk warnings that appear in cigarette advertisements and labels when the messages include images.

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Research presented at the ASCO Annual Meeting in June included these two clinical trials in advanced, metastatic non-small cell lung cancer.

Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

New study reveals that widespread molecular screening of non–small cell lung cancer is feasible and can be performed outside of large academic medical centers.

The administration of nab-paclitaxel plus carboplatin results in a significantly higher ORR than conventional solvent-based paclitaxel with carboplatin in previously untreated patients with advanced NSCLC.

Three medical societies have joined in endorsing low-dose computed tomography screening for patients at high risk of developing lung cancer.

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

The addition of bevacizumab to first-line carboplatin-paclitaxel did not prolong survival in Medicare recipients with advanced non–small cell lung cancer.